SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Earnings
Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.
March 4, 2026
 · 
9 min read
 · 
Tristan Manalac
Person jumping to arrow with another direction, in vintage colors stock illustration
Venture capital
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.
March 3, 2026
 · 
3 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing traditional drug development to accelerate innovation, advance precision medicine, and address clinically meaningful questions.
March 3, 2026
 · 
1 min read
 · 
BioSpace Insights
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
MASH
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Dream Birds Flying Away, the birds flying out of a bird an open cage, the birds released from a cage, freedom concept. birds set free vector illustration.
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme elevations in one patient, who died a few days later.
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hurdles along a path ending in an arrow
Complete response letters
REGENXBIO’s Hunter Rejection Hinged on Inadequate Controls, Surrogate Endpoint
In a complete response letter published by the FDA on Monday, the agency said a resubmission for REGENXBIO’s Hunter syndrome gene therapy should provide evidence of normalized or improved biomarker levels or neurodevelopmental outcomes.
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Downtown Holly Springs , North Carolina,
Manufacturing
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
March 3, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Lowkey dramatic view of sun beams breaking through a dense cumulus cloudscape. Background and inspiration
Opinion
Navigating the FDA After the Storm To Advance Drug Candidates
Here’s how drug developers can best approach interactions with the agency following last year’s seismic changes to its leadership, workforce and policies.
March 3, 2026
 · 
4 min read
 · 
John Kirk
An angry and determined man yelling and instigating a crowd during a rally. Boss speech in a conference. Vector illustration
FDA
FDA’s Circle of Trust Is Shrinking, Making Many Decisions Feel Like ‘Fiat’
FDA decisions lack majority consensus, experts agree, possibly leading to less nuanced verdicts on new drug applications. This type of “fiat” decision-making, as multiple regulatory experts have called it, is also bleeding into the agency’s policymaking.
March 3, 2026
 · 
4 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS